DK2707391T3 - Antistoffer mod her3 - Google Patents

Antistoffer mod her3 Download PDF

Info

Publication number
DK2707391T3
DK2707391T3 DK12719763.0T DK12719763T DK2707391T3 DK 2707391 T3 DK2707391 T3 DK 2707391T3 DK 12719763 T DK12719763 T DK 12719763T DK 2707391 T3 DK2707391 T3 DK 2707391T3
Authority
DK
Denmark
Prior art keywords
antibody
her3
seq
ser
gly
Prior art date
Application number
DK12719763.0T
Other languages
English (en)
Inventor
Abdelhakim Kharrat
Olivier Dubreuil
Yassamine Lazrek
Philippe Mondon
Khalil Bouayadi
Thierry Chardes
Andre Pelegrin
Christel Larbouret
Nadege A Gaborit
Original Assignee
Gamamabs Pharma
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamamabs Pharma, Inst Nat Sante Rech Med filed Critical Gamamabs Pharma
Application granted granted Critical
Publication of DK2707391T3 publication Critical patent/DK2707391T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

1. Anti-HER3-antistof, som omfatter: - en tung kæde, hvor det variable domæne omfatter SEQ ID NO: 1 for H-CDR1, SEQ ID NO: 2 for H-CDR2 og SEQ ID NO: 3 for H- CDR3; og - en let kæde, hvor det variable domæne omfatter SEQ ID NO: 4 for L-CDR1, SEQ ID NO: 5 for L-CDR2 og SEQ ID NO: 6 for L- CDR3 .
2. Antistof ifølge krav 1, hvor det variable domæne af den tunge kæde har aminosyresekvensen ifølge SEQ ID NO: 7.
3. Antistof ifølge et hvilket som helst af kravene 1 eller 2, hvor det variable domæne af den lette kæde har aminosyresekvensen ifølge SEQ ID NO: 8.
4. Antistof ifølge et hvilket som helst af kravene 1-3, hvor antistoffet er valgt fra gruppen bestående af et antistof, som omfatter det variable domæne af en tung kæde, hvilket variable domæne har aminosyresekvensen ifølge SEQ ID NO: 7, og det variable domæne af en let kæde, hvilket variable domæne har aminosyresekvensen ifølge SEQ ID NO: 8.
5. Antistof ifølge et hvilket som helst af kravene 1-4, hvor antistoffet er et humant antistof.
6. Antistof ifølge et hvilket som helst af kravene 1-5, hvor antistoffet er et antistoffragment valgt fra gruppen bestående af Fv, Fab, F(ab')2, Fab', dsFv, scFv, sc(Fv)2 og diabodies.
7. Farmaceutisk sammensætning, som omfatter et antistof ifølge et hvilket som helst af kravene 1-6 og en farmaceutisk acceptabel bærer.
8. Antistof ifølge et hvilket som helst af kravene 1-6 til anvendelse som lægemiddel.
9. Antistof ifølge et hvilket som helst af kravene 1-6 til anvendelse ved behandling af cancer.
DK12719763.0T 2011-05-13 2012-05-11 Antistoffer mod her3 DK2707391T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305583 2011-05-13
PCT/EP2012/058769 WO2012156309A1 (en) 2011-05-13 2012-05-11 Antibodies against her3

Publications (1)

Publication Number Publication Date
DK2707391T3 true DK2707391T3 (da) 2018-02-05

Family

ID=46046250

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12719763.0T DK2707391T3 (da) 2011-05-13 2012-05-11 Antistoffer mod her3

Country Status (8)

Country Link
US (1) US9346883B2 (da)
EP (1) EP2707391B1 (da)
DK (1) DK2707391T3 (da)
ES (1) ES2657862T3 (da)
NO (1) NO2707391T3 (da)
PL (1) PL2707391T3 (da)
PT (1) PT2707391T (da)
WO (1) WO2012156309A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
CN111108123A (zh) * 2017-05-29 2020-05-05 加马玛布斯制药公司 癌症相关的免疫抑制抑制剂
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
KR101598229B1 (ko) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants

Also Published As

Publication number Publication date
WO2012156309A1 (en) 2012-11-22
ES2657862T3 (es) 2018-03-07
NO2707391T3 (da) 2018-04-07
EP2707391A1 (en) 2014-03-19
EP2707391B1 (en) 2017-11-08
PT2707391T (pt) 2018-02-06
US9346883B2 (en) 2016-05-24
US20140141019A1 (en) 2014-05-22
PL2707391T3 (pl) 2018-04-30

Similar Documents

Publication Publication Date Title
DK2707391T3 (da) Antistoffer mod her3
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN108424456B (zh) 特异于her3的结合分子及其用途
CN112513095B (zh) Her3抗原结合分子
JP6033293B2 (ja) 抗Ａｘｌ抗体及びその使用
JP6120833B2 (ja) 抗Ａｘｌ抗体及びその使用
JP2022071071A (ja) ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体
KR20210109520A (ko) 항체 및 이의 용도
KR20170070076A (ko) 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
TW200848428A (en) Novel antibodies
WO2015048008A2 (en) Binding molecules specific for her3 and uses thereof
JP2022500072A (ja) Ｎｔｓｒ１に特異的な抗体およびその使用
KR20160101909A (ko) 뉴레귤린 알로스테릭 항-her3 항체
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
EP2985292A1 (en) Epidermal growth factor receptor antibody
EP3183342B1 (en) Method for prophylaxis and/or treatment of erbb1 positive cancers
WO2017072150A1 (en) Anti-nrg1 (heregulin) antibodies and uses thereof
HK40075856A (en) Her3 antigen-binding molecules
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK1233282B (en) Anti-mcam antibodies and associated methods of use
NZ625046B2 (en) Binding molecules specific for her3 and uses thereof